Engineered immune cells take on childhood leukemia in early trial
NCT ID NCT02650414
First seen Jan 07, 2026 · Last updated Jun 14, 2026 · Updated 20 times
Summary
This study tests a one-time treatment using the patient's own immune cells, modified to target a protein called CD22 on leukemia cells. It is for children and young adults whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe and possible to make, while also checking if it can put the cancer into remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.